Natera’s Signatera wins Japan PMDA approval as companion diagnostic in muscle-invasive bladder cancer

By Public Technologies
  • Natera won PMDA clearance in Japan for Signatera as a companion diagnostic in muscle-invasive bladder cancer.
  • Authorization supports MRD-guided adjuvant use of Roche’s Tecentriq (atezolizumab) in eligible post-surgery patients.
  • Commercial launch targeted for 1H 2027, pending final reimbursement and pricing decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220800BIZWIRE_USPR_____20260922_BW775835) on September 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk